Thus, DNA hypermethylation might contribute to the downregulation of ABR, PREX1, DOCK2, and DOCK4 in NSCLC, and the methylation profiles of the four key Rho GEFs may be novel biomarkers for lung cancer screening. This evidence concerns the gene DOCK4 and lung cancer.